We can only develop our expertise in our quest to ensure growth with the full commitment of all the men and women working within the group.
Today, Stago, a French group, employs nearly 2,000 people and has an increasingly international profile, with 35% of its employees currently working outside of France.
Stago, an unlisted independent family group, is seeking long-term development. All strategic decisions related to the organization, investment, acquisitions, partnerships, product development and new subsidiaries are carefully taken by the executive board and the president with a view to ensuring that the group endures.
Since 1962, Stago has dedicated its entire resources to developing the single field of coagulation. Permanently attuned to the medical and scientific communities, Stago is actively interested in all advances in this domain and in all the implications of such progress. Through this strategic approach, the company now has many major patents and innovations.
With more than 350 coagulation products, Stago offers a wide product portfolio through its highly effective commercial network (subsidiaries and distributors) and is a market leader in its field.
From routine tests to investigation of highly specialised parameters, some of which have been developed solely for specific studies throughout the world.
A complete range of analyzers and systems designed to meet the requirements of all laboratories (either autonomous or integrated into an Laboratory Automation System).
Use of flow cytometry to study platelets, e.g. cellular receptors and microparticles (BioCytex).
Development of standardised analytical systems.